Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasisâ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae), and ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is also using its platform to develop a novel class of antibiotics, non-β-lactam inhibitors of the penicillin-binding proteins (NBPs) (targeting Gram-negative infections). Source
No articles found.
Zoi, on a basic level, is an app that integrates with an Apple Watch and other wea...
Zoi, on a basic level, is an app that integrate...
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering a...
MacroGenics is a clinical-stage biopharmaceutic...
Cara Therapeutics is a clinical-stage biopharmaceutical company focused on develop...
Cara Therapeutics is a clinical-stage biopharma...
Ovid Therapeutics is a biopharmaceutical company focused exclusively on developing...
Ovid Therapeutics is a biopharmaceutical compan...
Aerpio Pharmaceuticals is a biopharmaceutical company focused on advancing first-i...
Aerpio Pharmaceuticals is a biopharmaceutical c...
Sarepta Therapeutics is a U.S. commercial-stage biopharmaceutical company focused ...
Sarepta Therapeutics is a U.S. commercial-stage...
SIGA Technologies, Inc. is a public, commercial-stage pharmaceutical company focus...
SIGA Technologies, Inc. is a public, commercial...
Join the National Investor Network and get the latest information with your interests in mind.